In a nutshell This article reviewed the importance of PET scanning during treatment for patients with Hodgkin lymphoma (HL). Some background PET scanning during treatment (interim PET) is used to guide therapy for patients with newly diagnosed HL. Depending on the scan results, treatment can be decreased, increased, or changed to a different...
Read MoreHodgkin’s lymphoma Posts on Medivizor
Evaluating BEGEV chemotherapy before a stem cell transplant for hard-to-treat Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of BEGEV chemotherapy for patients with relapsed or unresponsive Hodgkin lymphoma (HL) before a stem cell transplant. The authors concluded that this regimen was safe and effective for these patients. Some background Chemotherapy, followed by a stem cell transplant (SCT), remains the standard of...
Read MoreEvaluating ESHAO chemotherapy for patients with hard-to-treat Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of ESHAOx chemotherapy for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study found that this regimen is effective, with manageable side effects. Some background Most patients with HL respond well to initial treatment. However, some...
Read MoreEvaluating the combination of brentuximab vedotin and bendamustine in hard to treat Hodgkin lymphoma.
In a nutshell This study examined the safety and effectiveness of combining brentuximab vedotin (Adcetris) and bendamustine (Treanda) in patients with reoccurring or unresponsive Hodgkin lymphoma (HL). The authors concluded that this regimen shows promise in HL which is difficult to treat. Some...
Read MoreEvaluating outcomes of allo-HSCT for patients with Hodgkin lymphoma
In a nutshell This study evaluated the outcomes of patients with Hodgkin lymphoma (HL) after a first allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that allo-HSCT is promising for these patients, with low relapse rates. Some background Autologous (auto) HSCT is the usual next step for patients with HL that...
Read MoreHow effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?
In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....
Read MoreAre prognostic scores still useful for predicting outcomes for patients with advanced Hodgkin’s lymphoma?
In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...
Read MoreTreatment approaches for patients with advanced Hodgkin’s lymphoma
In a nutshell This article reviewed different treatment approaches for patients with advanced Hodgkin's lymphoma (HL). Some background HL is a type of blood cancer of the lymphatic system. HL can be classified in different ways. In limited HL, cancer is found in one or two sites in the lymphatic system. In advanced HL, cancer is found on...
Read MoreGuidelines for the treatment of patients with Hodgkin’s lymphoma
In a nutshell This article outlined recommended treatments for patients with Hodgkin's lymphoma (HL). Some background HL is a type of blood cancer of the lymphatic system. HL can be classified in different ways. In limited HL, cancer is found in one or two sites in the lymphatic system. In advanced HL, cancer is found on both sides of...
Read MoreEvaluating gemcitabine plus bendamustine for patients with non-responsive Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of gemcitabine (Gemzar) plus bendamustine (Treanda) in patients with Hodgkin lymphoma (HL) that has come back or stopped responding to treatment. This study found that this combination was well-tolerated and effective for these patients. Some background Immunotherapy remains a...
Read MoreEvaluating combined modality treatment for young adults with Hodgkin lymphoma
In a nutshell This study determined the safety and effectiveness of combined modality treatment for young adults with classical Hodgkin lymphoma (cHL). This study concluded that this treatment approach was well-tolerated and effective for these patients. Some background Chemotherapy regimens for pediatric patients with cHL are different from...
Read MoreEvaluating the risk of lung side effects in older patients with Hodgkin lymphoma
In a nutshell This study investigated whether older patients with Hodgkin lymphoma (HL) were at high risk for developing lung side effects when treated with bleomycin (Blenoxane). The authors found that the odds of developing lung side effects increased significantly with age in these patients. Some background For patients with HL, age is one of...
Read More
